open access

Vol 48, No 4 (2017)
Prace poglądowe / Reviews
Published online: 2017-10-01
Submitted: 2016-11-13
Get Citation

Efficacy and safety of bosutinib in the second and third line of treatment in chronic myeloid leukemia

Bogdan Ochrem1, Tomasz Sacha21
DOI: 10.1016/j.achaem.2017.03.002
·
Acta Haematol Pol 2017;48(4):274-281.
Affiliations
  1. Clinical Hematology Unit, University Hospital in Cracow, Poland
  2. Department of Hematology, Jagiellonian University, Collegium Medicum, Poland

open access

Vol 48, No 4 (2017)
Prace poglądowe / Reviews
Published online: 2017-10-01
Submitted: 2016-11-13

Abstract

Tyrosine kinases inhibitors (TKIs) are the mainstay of chronic myeloid leukemia (CML) treatment. The choice of a specific TKI depends on its side effects, disease phase, ABL mutations, concomitant diseases, and reimbursement possibility. Bosutinib is a second generation TKI (2GTKI) approved for the treatment of patients with CML in all phases, previously treated with ≥1 TKI, who cannot be treated with imatinib, nilotinib or dasatinib. It is active against the majority of mutant BCR-ABL1, except T315I and V299L. Response rates in patients resistant or intolerant to imatinib treated with bosutinib are similar to those observed for other 2GTKI. Bosutinib may be also effective in patients with advanced phases of CML after other TKI failure. The most common side effects include gastrointestinal symptoms, rash, and increased transaminase activity. Bosutinib causes less cases of pleural effusion, hypercholesterolemia, hyperglycemia, and cardiovascular complications than other TKIs, therefore it is a very important therapeutic option for patients with these disorders.

Abstract

Tyrosine kinases inhibitors (TKIs) are the mainstay of chronic myeloid leukemia (CML) treatment. The choice of a specific TKI depends on its side effects, disease phase, ABL mutations, concomitant diseases, and reimbursement possibility. Bosutinib is a second generation TKI (2GTKI) approved for the treatment of patients with CML in all phases, previously treated with ≥1 TKI, who cannot be treated with imatinib, nilotinib or dasatinib. It is active against the majority of mutant BCR-ABL1, except T315I and V299L. Response rates in patients resistant or intolerant to imatinib treated with bosutinib are similar to those observed for other 2GTKI. Bosutinib may be also effective in patients with advanced phases of CML after other TKI failure. The most common side effects include gastrointestinal symptoms, rash, and increased transaminase activity. Bosutinib causes less cases of pleural effusion, hypercholesterolemia, hyperglycemia, and cardiovascular complications than other TKIs, therefore it is a very important therapeutic option for patients with these disorders.

Get Citation

Keywords

Leukemia; Myelogenous; Chronic; BCR-ABL Positive; Bosutinib

About this article
Title

Efficacy and safety of bosutinib in the second and third line of treatment in chronic myeloid leukemia

Journal

Acta Haematologica Polonica

Issue

Vol 48, No 4 (2017)

Pages

274-281

Published online

2017-10-01

DOI

10.1016/j.achaem.2017.03.002

Bibliographic record

Acta Haematol Pol 2017;48(4):274-281.

Keywords

Leukemia
Myelogenous
Chronic
BCR-ABL Positive
Bosutinib

Authors

Bogdan Ochrem
Tomasz Sacha

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl